Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia
Myelodysplastic/Myeloproliferative Diseases
Lymphoma

First Posted Date: 2003-06-06

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00062140

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-06-05

Last Posted Date: 2013-02-04

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00008203

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: methotrexate
Drug: ifosfamide
Drug: vincristine sulfate

First Posted Date: 2003-05-21

Last Posted Date: 2013-08-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 83

Registration Number: NCT00005977

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Oncology P.A., Dallas, Texas, United States

and more 116 locations

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Phase 2

Completed

Conditions: Brain Tumors
Central Nervous System Tumors
Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-05-19

Last Posted Date: 2013-08-23

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 168

Registration Number: NCT00003203

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada

and more 35 locations

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Phase 2

Completed

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

First Posted Date: 2003-05-09

Last Posted Date: 2013-07-10

Lead Sponsor: Chimeric Therapies

Registration Number: NCT00004255

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States
🇺🇸
Presbyterian-St Luke's Medical Center, Denver, Colorado, United States

and more 12 locations

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Testicular Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-05-07

Last Posted Date: 2013-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 451

Registration Number: NCT00060255

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

First Posted Date: 2003-05-07

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 3

Registration Number: NCT00060385

Locations: 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2003-05-07

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 16

Registration Number: NCT00060346

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States

and more 150 locations